Tag: Drug Conjugates

Appointment of Independent Director and Chairman of Audit Committee Expands Financial Expertise on Board Boca Raton, FL, July 20, 2021 -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for rare diseases, announced today that Marc Drimer, CPA has joined its Board of Directors as an independent director and Chairman of the Audit Committee. Mr. Drimer has over 35. Read More>>

Company Appoints Kapil Bharti, Ph.D., and Dimiter Dimitrov, Ph.D. to Scientific and Clinical Advisory Board Boca Raton, FL / iCrowd Newswire/ April 29, 2021 / Curative Biotechnology, Inc.  (OTC: CUBT) a development-stage biomedical company focused on novel therapies for rare diseases, announced today the Company's trading symbol change from "CTYX" to "CUBT".  As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and. Read More>>

Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatment; over the years, this upcoming class of targeted therapeutic agents has generated significant enthusiasm within the medical science community Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption. Read More>>